Free Trial

Journey Medical (DERM) Competitors

Journey Medical logo
$6.92 -0.19 (-2.67%)
As of 07/8/2025 04:00 PM Eastern

DERM vs. FBIO, AUTL, STOK, URGN, PHAT, RLAY, ABUS, TNGX, CDXC, and DNTH

Should you be buying Journey Medical stock or one of its competitors? The main competitors of Journey Medical include Fortress Biotech (FBIO), Autolus Therapeutics (AUTL), Stoke Therapeutics (STOK), Urogen Pharma (URGN), Phathom Pharmaceuticals (PHAT), Relay Therapeutics (RLAY), Arbutus Biopharma (ABUS), Tango Therapeutics (TNGX), ChromaDex (CDXC), and Dianthus Therapeutics (DNTH). These companies are all part of the "medical" sector.

Journey Medical vs. Its Competitors

Journey Medical (NASDAQ:DERM) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, earnings, valuation, analyst recommendations, media sentiment, dividends, profitability and risk.

Journey Medical has a net margin of -14.76% compared to Fortress Biotech's net margin of -71.24%. Journey Medical's return on equity of -52.03% beat Fortress Biotech's return on equity.

Company Net Margins Return on Equity Return on Assets
Journey Medical-14.76% -52.03% -11.28%
Fortress Biotech -71.24%-4,712.53%-27.67%

7.3% of Journey Medical shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 15.0% of Journey Medical shares are held by company insiders. Comparatively, 27.9% of Fortress Biotech shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Journey Medical has higher earnings, but lower revenue than Fortress Biotech. Journey Medical is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Journey Medical$56.13M2.87-$14.67M-$0.39-17.74
Fortress Biotech$57.67M0.99-$46M-$2.23-0.87

Journey Medical has a beta of 0.8, indicating that its stock price is 20% less volatile than the S&P 500. Comparatively, Fortress Biotech has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500.

Journey Medical currently has a consensus price target of $9.50, suggesting a potential upside of 37.28%. Fortress Biotech has a consensus price target of $21.00, suggesting a potential upside of 988.08%. Given Fortress Biotech's higher possible upside, analysts clearly believe Fortress Biotech is more favorable than Journey Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Journey Medical
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Fortress Biotech
0 Sell rating(s)
0 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
3.00

In the previous week, Journey Medical had 1 more articles in the media than Fortress Biotech. MarketBeat recorded 1 mentions for Journey Medical and 0 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 0.00 beat Journey Medical's score of -0.76 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company Overall Sentiment
Journey Medical Negative
Fortress Biotech Neutral

Summary

Journey Medical beats Fortress Biotech on 8 of the 15 factors compared between the two stocks.

Get Journey Medical News Delivered to You Automatically

Sign up to receive the latest news and ratings for DERM and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding DERM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

DERM vs. The Competition

MetricJourney MedicalMED IndustryMedical SectorNASDAQ Exchange
Market Cap$165.63M$2.39B$5.47B$8.95B
Dividend YieldN/A1.80%5.25%4.06%
P/E Ratio-17.748.9827.0020.10
Price / Sales2.87729.50428.95120.24
Price / CashN/A159.8036.8257.86
Price / Book7.604.517.985.56
Net Income-$14.67M$31.26M$3.16B$248.40M
7 Day Performance-1.70%3.57%2.39%4.67%
1 Month Performance-3.35%1.28%2.18%6.64%
1 Year Performance23.35%1.08%33.82%21.31%

Journey Medical Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
DERM
Journey Medical
1.8438 of 5 stars
$6.92
-2.7%
$9.50
+37.3%
+21.6%$165.63M$56.13M-17.7490Analyst Downgrade
FBIO
Fortress Biotech
2.1251 of 5 stars
$1.91
+1.6%
$21.00
+999.5%
+10.3%$55.59M$57.67M-0.86170
AUTL
Autolus Therapeutics
2.1407 of 5 stars
$2.26
-4.6%
$9.32
+312.4%
-36.7%$630.76M$10.12M-2.57330
STOK
Stoke Therapeutics
3.9985 of 5 stars
$11.69
+1.8%
$23.20
+98.5%
-7.2%$626.77M$36.56M14.80100
URGN
Urogen Pharma
4.543 of 5 stars
$13.49
-0.7%
$32.86
+143.6%
-14.8%$626.14M$90.40M-4.24200Analyst Forecast
PHAT
Phathom Pharmaceuticals
3.3152 of 5 stars
$8.66
-2.9%
$17.50
+102.1%
-13.5%$622.74M$55.25M-1.65110
RLAY
Relay Therapeutics
2.5396 of 5 stars
$3.55
-2.2%
$17.67
+397.7%
-44.6%$622.34M$10.01M-1.59330Positive News
ABUS
Arbutus Biopharma
1.4539 of 5 stars
$3.14
-3.1%
$5.50
+75.2%
-2.5%$620.55M$6.17M-7.6690
TNGX
Tango Therapeutics
2.2355 of 5 stars
$5.43
-4.7%
$12.20
+124.7%
-35.8%$617.85M$40.99M-4.4590
CDXC
ChromaDex
3.1938 of 5 stars
N/A$9.03
+∞
N/A$611.50M$99.60M787.29120
DNTH
Dianthus Therapeutics
1.8215 of 5 stars
$18.25
-3.2%
$53.00
+190.4%
-35.4%$606.22M$6.24M-6.3480

Related Companies and Tools


This page (NASDAQ:DERM) was last updated on 7/9/2025 by MarketBeat.com Staff
From Our Partners